NANBIOSIS Unit 2 (CAbS) participates in the III SENTIATECH Meeting, showcasing nanobiotechnology and diagnostics for health risk monitoring.
NANBIOSIS is actively represented at the III SENTIATECH Meeting | Science, Technology & Health Risk Monitoring through the Nb4D research group, in which NANBIOSIS Unit 2 “CAbS” is integrated. This third edition of the SENTIATECH Meeting focuses on presenting the SENTIATECH platform and strengthening collaboration between research centers and industry to tackle current and emerging challenges in defense and chemical–biological risk management.
During the meeting, Dr. J. Pablo Salvador, Tenured Scientist and member of the Nb4D group, is coordinating Working Group 4 (WG4), dedicated to the monitoring and diagnosis of health-related risks. This working group addresses key scientific and technological strategies for early detection, surveillance, and response to threats affecting human health.
In parallel, the Nb4D group has a dedicated exhibition space at the event, where it is presenting its research and technological capabilities in nanobiotechnology, diagnostics, and antibody-based solutions. As experts in immunoassay development, the group showcases advanced tools for the detection of pathogens, toxins, chemical contaminants, and other threatening substances, reinforcing the relevance of NANBIOSIS infrastructures in high-impact risk scenarios.
The SENTIATECH Meeting brings together stakeholders from academia, research institutions, and industry with the shared objective of:
- Presenting technological solutions for defense and chemical–biological risk scenarios
- Fostering collaborative synergies between science and industry
- Defining a strategic agenda to address emerging and future risks effectively
Participation in this forum highlights the commitment of NANBIOSIS and its units to technology transfer, innovation, and the application of cutting-edge science to protect human health and security.
What is NANBIOSIS?
The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).
If you want to collaborate with us, visit our Open Call page.
In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.
NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:
